Giants of Cancer Care® Program Inductees

Gynecologic Cancers

David M. Gershenson, MD

The University of Texas MD Anderson Cancer Center

Gershenson is a professor of gynecologic oncology at The University of Texas MD Anderson Cancer Center.
He played a major role in designing and initiating clinical trials focused on novel therapeutics for patients with rare ovarian cancers.
In 2009, Gershenson was the principal investigator for a retrospective study establishing that chemoresistance was prevalent in low-grade serious ovarian carcinoma, suggesting that targeted agents would be more effective in this disease.
Gershenson was a co-author on a 2017 study establishing the poor prognosis associated with advanced-stage or recurrent ovarian clear cell and mucinous carcinomas.
He was the principal investigator for the phase 2/3 GOG281/LOGS trial (NCT02101788), which showed that the MEK1/2 inhibitor trametinib (Mekinist) extended progression-free survival in patients with low-grade serous ovarian cancer compared with the existing standard-of-care regimens.
Gershenson’s participation on several committees and organizations underscore his commitment to raising awareness of rare ovarian tumors. He is a former chair of the Rare Tumor Working Group of the Gynecologic Cancer Intergroup and previously served as the chair of the Rare Tumor Committee of the Gynecologic Oncology Group.

Home

)

SUPPORTED BY